PTGFR (prostaglandin F receptor) is a G protein-coupled receptor located on chromosome 1 that binds prostaglandin F2-alpha (PGF2α) and activates phosphatidylinositol-calcium signaling pathways 1. The receptor mediates multiple physiological processes including parturition and endometrial breakdown during menstruation 12. PTGFR undergoes alternative splicing to generate functionally distinct variants, with variant 1 serving as the primary PGF2α receptor while variants 2-7 may modulate signaling through heteromeric complexes 1. Clinically, PTGFR polymorphisms significantly influence therapeutic response. PTGFR gene variants (rs3766355, rs3753380) correlate with intraocular pressure response to latanoprost in glaucoma patients, with specific alleles predicting better drug efficacy 34. In retinal pathology, PGF2α/PTGFR axis upregulation promotes pathological angiogenesis in proliferative diabetic retinopathy through ELR+ CXC chemokine release via Gq/CAMK2G/p38 signaling; PTGFR inhibition attenuates oxygen-induced retinopathy in mice 5. Additionally, PTGFR emerges as an immune-related hub gene in keloid pathogenesis, with dysregulated expression in pro-inflammatory fibroblasts affecting disease progression 6. These findings position PTGFR as a promising therapeutic target for glaucoma, retinal neovascularization, and fibroproliferative diseases.